MacroGenics Operating Income Over Time
| MGNX Stock | USD 1.73 0.02 1.14% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out MacroGenics Performance and MacroGenics Correlation. MacroGenics | Build AI portfolio with MacroGenics Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MacroGenics. Expected growth trajectory for MacroGenics significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive MacroGenics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.70) | Earnings Share (1.21) | Revenue Per Share | Quarterly Revenue Growth (0.34) | Return On Assets |
Understanding MacroGenics requires distinguishing between market price and book value, where the latter reflects MacroGenics's accounting equity. The concept of intrinsic value - what MacroGenics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push MacroGenics' price substantially above or below its fundamental value.
Understanding that MacroGenics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MacroGenics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, MacroGenics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare MacroGenics and related stocks such as Ovid Therapeutics, Context Therapeutics, and Clene Inc Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OVID | (447 K) | (447 K) | (447 K) | (447 K) | (447 K) | (13.2 M) | (22.5 M) | (65 M) | (52.9 M) | (61.4 M) | (81.4 M) | 124.2 M | (55.5 M) | (59.3 M) | (61.9 M) | (55.7 M) | (52.9 M) |
| CNTX | (33.2 M) | (33.2 M) | (33.2 M) | (33.2 M) | (33.2 M) | (33.2 M) | (33.2 M) | (24.1 M) | (5.4 M) | (5.4 M) | (2.6 M) | (10.5 M) | (15.4 M) | (25.1 M) | (29.9 M) | (26.9 M) | (28.3 M) |
| CLNN | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (323.9 K) | (16.3 M) | (20.2 M) | (50 M) | (48.4 M) | (40.5 M) | (33.1 M) | (29.8 M) | (31.3 M) |
| WHWK | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (2.5 M) | (111.2 M) | (62.7 M) | (71.9 M) | (67.5 M) | (60.7 M) | (63.7 M) |
| STTK | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (25.1 M) | (36.9 M) | (45.3 M) | (103.3 M) | (92 M) | (80.6 M) | (72.5 M) | (76.1 M) |
| CNTB | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (30.3 M) | (99.2 M) | (117.7 M) | (62.1 M) | (22.5 M) | (20.2 M) | (21.2 M) |
| ORMP | (50 K) | (2.4 M) | 2.9 M | (4.3 M) | (5.9 M) | (7.4 M) | (10 M) | (10.8 M) | (13.5 M) | (14.6 M) | (11.8 M) | (24.2 M) | (40.6 M) | (15.8 M) | (12.8 M) | (11.5 M) | (12.1 M) |
| ZNTL | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (46.8 M) | (118.8 M) | (216.5 M) | (227.3 M) | (299.5 M) | (191.2 M) | (172.1 M) | (180.7 M) |
| COYA | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (4.9 M) | (9.8 M) | (7.9 M) | (17.2 M) | (15.5 M) | (14.7 M) |
| IFRX | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (6.9 M) | (19.4 M) | (37.5 M) | (63.9 M) | (38.9 M) | (56.4 M) | (55.1 M) | (44.9 M) | (53 M) | (47.7 M) | (50.1 M) |
MacroGenics and related stocks such as Ovid Therapeutics, Context Therapeutics, and Clene Inc Operating Income description
Operating Income is the amount of profit realized from MacroGenics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of MacroGenics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| MacroGenics | MGNX |
| Classification | Cancer Fighters |
| Business Address | 9704 Medical Center |
| Exchange | NASDAQ Exchange |
USD 1.73
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.